Magtein Receives UK Novel Food Approval Two Years Post-EU Clearance

London, United Kingdom — 20 March 2026

Magnesium L-threonate, commercially known as Magtein, has officially received Novel Food approval for the United Kingdom. This significant regulatory milestone follows its authorisation within the European Union two years prior, effectively harmonising its legal status across both markets for supplement applications. The proprietary ingredient, developed by Magceutics and licensed by AIDP, is positioned primarily for cognitive health support, addressing areas such as memory, learning, and overall brain function.

The protracted gap between EU and UK approvals underscores the divergence in regulatory processes post-Brexit. While the ingredient has been available to EU formulators since 2024, UK-based brand owners faced uncertainty and a competitive lag. This new approval streamlines market entry for Magtein-containing products in the UK, potentially stimulating innovation in the country's rapidly expanding cognitive supplement sector. Manufacturers can now leverage the ingredient's existing scientific dossier and safety data to accelerate product development cycles for the UK consumer base.

The authorisation specifically enables the use of Magtein in food supplements at specified dosages. This clarity is crucial for procurement and formulation teams, allowing for confident investment in inventory and marketing strategies targeted at the UK. The approval aligns with a broader industry trend towards scientifically-substantiated ingredients, particularly in the brain health category, which continues to attract significant consumer interest driven by an ageing population and increased awareness of mental wellbeing.

Given the ingredient's previous EU success, this UK clearance is expected to catalyse new product launches across multiple retail channels, including pharmacies like Boots, health food stores like Holland & Barrett, and major e-commerce platforms. The focus on establishing reference intakes for ingredients like creatine (NutraIngredients, 18 March 2026) suggests a growing regulatory emphasis on robust scientific backing, to which Magtein's Novel Food status contributes.

What this means for United Kingdom

UK supplement manufacturers can immediately proceed with formulating products containing Magtein, capitalising on accelerated market entry compared to previous waiting periods. Brand owners now possess a direct competitive tool to match EU novel cognitive health products, shortening time-to-market by up to six months. Regulatory teams must ensure all Magtein-containing products adhere strictly to the specified dosage limits outlined in the Novel Food authorisation to avoid compliance issues with the FSA. Procurement leads should anticipate increased demand and potential adjustments to MOQ requirements from ingredient suppliers, warranting proactive supply chain management. This approval creates clear opportunities for UK brands to differentiate within the competitive cognitive health segment.

What this means for United Kingdom

UK supplement manufacturers can immediately proceed with formulating products containing Magtein, capitalising on accelerated market entry compared to previous waiting periods. Brand owners now possess a direct competitive tool to match EU novel cognitive health products, shortening time-to-market by up to six months. Regulatory teams must ensure all Magtein-containing products adhere strictly to the specified dosage limits outlined in the Novel Food authorisation to avoid compliance issues with the FSA. Procurement leads should anticipate increased demand and potential adjustments to MOQ requirements from ingredient suppliers, warranting proactive supply chain management. This approval creates clear opportunities for UK brands to differentiate within the competitive cognitive health segment.

For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.